Turing sidesteps list-price discount on jacked-up therapy Daraprim

Turing Pharmaceuticals has been saying for a while now that it would lower the price of its toxoplasmosis med, Daraprim, responding to growing backlash from lawmakers and the public after it bought the drug in August and jacked up its price by more than 5,000%. Now the company is taking a different route, opting to negotiate discounts with hospitals rather than cut the drug's list price. More from FiercePharma